Appreciate the comment, beartrap12. One thing worth watching closely: Mill Creek doesn’t appear to have a therapeutic product of its own. What we’re likely seeing is a large scale implementation strategy, a process that looks almost identical to one already running. Nearly point for point.
And that is not coincidence. The product in question might not be separate at all. It may be the same architecture, the same immune engine, just stripped of its autologous tumor input. Who is behind it has not been named, but the blueprint is unmistakable.
DCVax-L was not built as a one off therapy. It is a modular immune platform. Dendritic cells capture signals, migrate to lymph nodes, activate T cells, and coordinate systemic response. No drug needed. The body becomes the treatment.
That structure is not limited to glioblastoma. And it was never just about cancer.
Think back to early COVID. Moderna designed its vaccine sequence two days after the virus was published, but it still took more than six weeks to manufacture the first clinical batch, and nearly eleven months before the first public dose. That delay from January to December was the dead zone. No vaccine. No protection. Just ventilators and body bags.
Now imagine this instead.
You identify the virus. Within days, you produce a lysate or recombinant spike protein. Blood is drawn from the patient. Flaskworks runs their cells through its closed system. By day four, you have manufactured trained dendritic cells that can direct the patient’s immune system to attack. Not in theory. In real time.
You do not need a new drug. You do not need mass formulation. You do not even need cold chain. You just need a decision.
Flaskworks can do this in a week. The system already exists. The safety profile is already established. The only thing missing was deployment.
And the truth is, this could have worked.
Mechanistically, it is sound. Dendritic cells are the body’s most powerful antigen presenting cells. When you load them with a viral lysate, they do not need permission to act. They absorb, migrate, present, and activate T cells directly. No adjuvants. No guesswork.
This is not speculation. Dr. Pawel Kalinski at Roswell Park used a version of this strategy in clinical models. His dendritic cell vaccine was pulsed with viral or tumor derived antigens and matured using a defined cytokine cocktail to promote migration and T cell activation. The patents covering this process are owned by Roswell Park and licensed exclusively to Northwest Biotherapeutics.
The science is validated. The intellectual property is secured. The immunology holds up. The infrastructure was the only missing link.
With automation in place, blood could have been drawn, cells run through Flaskworks, and reinfused within days. Not for everyone, but for the elderly, the immunocompromised, the exposed. The people who could not wait.
This would not just have bridged the gap. It could have changed the outcome. A break in the chain of transmission. A trained immune response while the rest of the world was still stuck in first gear.
The fact that this was not used should raise more questions than answers.
And then there is Merck. One of the most strategically positioned companies in immuno oncology, now tied to multiple dendritic cell trials run in parallel with Kalinski’s group and Mill Creek. The alignment is there. Whether through acquisition, indirect coordination, or forward positioning, they appear to be walking the same path Northwest Biotherapeutics mapped years ago. Several trials sponsored by Roswell Park or Kalinski’s lab have combined dendritic cell vaccines with checkpoint inhibitors like pembrolizumab. These include studies in colorectal cancer, head and neck cancer, and solid tumors, with Merck often providing drug or in-kind support. The protocols are structurally similar to DCVax-Direct, using antigen loaded dendritic cells matured under Kalinski’s patented cytokine conditions. That intellectual property belongs to Roswell Park and remains exclusively licensed to Northwest Biotherapeutics.
Thanks for keeping the conversation here. It is where the next chapter begins.
Bullish
Market Data 
Markets 
